Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Abstract Background The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. Methods ACTIVATE was a multi...

Full description

Bibliographic Details
Main Authors: Evan B. Cunningham, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S. Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Maria Christine Thurnheer, Gregory J Dore, Jason Grebely, on behalf of the ACTIVATE Study Group
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Infectious Diseases
Subjects:
Hepatitis C
Treatment
PWID
Injection drug use
Adherence
Online Access:http://link.springer.com/article/10.1186/s12879-017-2517-3

Internet

http://link.springer.com/article/10.1186/s12879-017-2517-3

Similar Items